First shipment of sachets is a new important milestone for the project and will reduce carbon footprint

Brain

Following the successful submission of the IMPD for the updated presentation of the medication into the clinical trial and obtaining the approval of the Competent Authorities, the first shipment of sachets to the centers took place this April 2022. This is an important milestone for the project, as it will allow the reduction of costs related to logistics, storage, and dispensing of the medicine, besides reducing the number of shipments and the carbon footprint with a positive impact on the environment. We expect it will have a significant impact on adherence to treatment in the future.